Lenvima

Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer
Merck and Eisai's Keytruda-Lenvima combo chalks up 2 more losses, this time in non-small cell lung cancer
Fierce Pharma
Merck
Eisai
Keytruda
Lenvima
melanoma
colorectal cancer
non-small cell lung cancer
Flag link:
Merck, Eisai Drop Phase III Keytruda-Lenvima Trial for Head and Neck Cancer
Merck, Eisai Drop Phase III Keytruda-Lenvima Trial for Head and Neck Cancer
BioSpace
Merck
Eisai
Keytruda
Lenvima
clinical trials
head and neck cancer
Flag link:
Merck and Eisai tease results for renal carcinoma treatment
Merck and Eisai tease results for renal carcinoma treatment
Clinical Trials Arena
Merck
Eisai
ASCO 2023
Lenvima
Keytruda
renal cell carcinoma
Flag link:
Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail
Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail
BioSpace
Merck
Keytruda
Eisai
Lenvima
melanoma
clinical trials
cancer
colorectal cancer
Flag link:
Medivir completes initial Phase Ib part of HCC therapy trial
Medivir completes initial Phase Ib part of HCC therapy trial
Clinical Trials Arena
Medvir
fostrox
Lenvima
hepatocellular carcinoma
clinical trials
Flag link:
Merck's Keytruda, on a losing streak, fails in once FDA-rejected liver cancer use and prostate cancer—again
Merck's Keytruda, on a losing streak, fails in once FDA-rejected liver cancer use and prostate cancer—again
Fierce Pharma
Merck
Keytruda
FDA
liver cancer
Lenvima
Flag link:
ASCO: Merck's Keytruda combo data could spark hope for lymphoma patients who lack options
ASCO: Merck's Keytruda combo data could spark hope for lymphoma patients who lack options
Fierce Biotech
ASCO 2022
Merck
Keytuda
Lynparza
Lenvima
Flag link:
Merck, Eisai notch full approval for Keytruda-TKI inhibitor combo in advanced endometrial cancer
Merck, Eisai notch full approval for Keytruda-TKI inhibitor combo in advanced endometrial cancer
Endpoints
Merck
Keytruda
Lenvima
endometrial cancer
FDA
Flag link:
Merck breathes a sigh of relief as Keytruda-Lenvima combo aces confirmatory study in endometrial cancer
Merck breathes a sigh of relief as Keytruda-Lenvima combo aces confirmatory study in endometrial cancer
Endpoints
Merck
FDA
Keytruda
Eisai
Lenvima
clinical trials
endometrial cancer
Flag link:
Merck's Keytruda Plus Eisai's Lenvima Could Open New Standard of Care in Renal Cancer
Merck's Keytruda Plus Eisai's Lenvima Could Open New Standard of Care in Renal Cancer
BioSpace
Merck
ASCO GU
Keytruda
Eisai
Lenvima
renal cell carcinoma
Flag link:
Could Keytruda/Lenvima Combo Help Treat Advanced Renal Cell Carcinoma?
Could Keytruda/Lenvima Combo Help Treat Advanced Renal Cell Carcinoma?
BioSpace
Merck
Eisai
Keytruda
Lenvima
clinical trials
advanced renal cell carcinoma
Flag link:
ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show
ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show
Fierce Pharma
Merck
Eisai
Keytruda
Lenvima
ovarian cancer
colorectal cancer
Flag link:
FDA bars the door — for now — against Merck’s star cancer drug after Roche beat them to the punch
FDA bars the door — for now — against Merck’s star cancer drug after Roche beat them to the punch
Endpoints
Merck
FDA
complete response letter
Keytruda
Eisaid
Lenvima
hepatocellular carcinoma
Roche
Flag link:
ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data
ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data
Fierce Pharma
Merck
Eisai
liver cancer
ASCO 2020
Keytrua
Lenvima
clinical trials
Flag link:
ESMO: Merck, Eisai detail Keytruda-Lenvima combo results after triple endometrial cancer OK
ESMO: Merck, Eisai detail Keytruda-Lenvima combo results after triple endometrial cancer OK
Fierce Pharma
Merck
Eisai
Keytruda
Lenvima
endometrial cancer
ESMO
Flag link:
Merck, Eisai's Keytruda-Lenvima combo wins simultaneous OKs in U.S., Canada and Australia
Merck, Eisai's Keytruda-Lenvima combo wins simultaneous OKs in U.S., Canada and Australia
Fierce Pharma
Merck
Keytruda
Eisai
Lenvima
endometrial cancer
Canada
Australia
Flag link:
Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma
Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma
CP Wire
China
Eisai
Merck
Lenvima
liver cancer
HCC
Flag link:
Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma
Eisai
Merck
Lenvima
liver cancer
hepatocellular carcinoma
Flag link:
European Commission Approves New First Line Treatment for Advanced or Unresectable Hepatocellular Carcinoma – First in a Decade
European Commission Approves New First Line Treatment for Advanced or Unresectable Hepatocellular Carcinoma – First in a Decade
CP WIre
Eisai
Merck
Lenvima
hepatocellular carcinoma
Europe
Flag link:
European Commission Approves New First Line Treatment for Advanced or Unresectable Hepatocellular Carcinoma – First in a Decade
Eisai
Merck
Lenvima
hepatocellular carcinoma
Flag link:

Pages